Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections

Clinical Therapeutics

Volumn 26, Issue 10, 2004, Pages 1652-1662

  Hooshmand Rad, Roya ^a   Reed, Michael D ^b   Chu, Alice ^a   Gotz, Vincent ^a   Morris, Jonathan A ^a   Weinberg, John ^c   Dominguez, Edward A ^d  

^a ProSanos Corporation   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Enzon Incorporated   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

amphotericin B lipid complex; dosage; duration of therapy; fungal infection; nephrotoxicity

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREATINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DATA ANALYSIS; DATA BASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; FUNGICIDAL ACTIVITY; HUMAN; INFANT; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MALE; MATHEMATICAL COMPUTING; MOULD; MYCOSIS; NEPHROTOXICITY; NEWBORN; PATIENT SELECTION; PROSPECTIVE STUDY; REGISTER; RETROSPECTIVE STUDY; SIDE EFFECT; SOLID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFANT; MALE; MIDDLE AGED; MYCOSES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 10444286064     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.10.010     Document Type: Article

References (47)

1. Bodey G., Bueltmann B., and Duguid W. Fungal infections in cancer patients: An international autopsy survey Eur J Clin Microbiol Infect Dis 11 1992 99 109
2. Paya C.V. Fungal infections in solid-organ transplantation Clin Infect Dis 16 1993 677 688
3. Bohme A., and Karthaus M. Systemic fungal infections in patients with hematologic malignancies: Indications and limitations of the antifungal armamentarium Chemotherapy 45 1999 315 324
4. Edmond M.B., Wallace S.E., and McClish D.K. Nosocomial bloodstream infections in United States hospitals: A three-year analysis Clin Infect Dis 29 1999 239 244
5. Marr K.A., Patterson T., and Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy Infect Dis Clin North Am 16 2002 875 894
6. Marr K.A., Patterson T., and Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy Infect Dis Clin North Am 16 2002 vi
7. Denning D.W. Therapeutic outcome in invasive aspergillosis Clin Infect Dis 23 1996 608 615
8. Morrison V.A., Haake R.J., and Weisdorf D.J. Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome Am J Med 96 1994 497 503
9. Lee D.G., Choi J.H., and Choi S.M. Two cases of disseminated mucormycosis in patients following allogeneic bone marrow transplantation J Korean Med Sci 17 2002 403 406
10. Ribes J.A., Vanover-Sams C.L., and Baker D.J. Zygomycetes in human disease Clin Microbiol Rev 13 2000 236 301
11. Gallis H.A., Drew R.H., and Pickard W.W. Amphotericin B: 30 Years of clinical experience Rev Infect Dis 12 1990 308 329
12. Bates D.W., Su L., and Yu D.T. Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis 32 2001 686 693
13. Harbarth S., Pestotnik S.L., and Lloyd J.F. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy Am J Med 111 2001 528 534
14. Wingard J.R., Kubilis P., and Lee L. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis Clin Infect Dis 29 1999 1402 1407
15. Gubbins P.O., Penzak S.R., and Polston S. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients Pharmacotherapy 22 2002 961 971
16. (Suppl) Kreis H. New strategies to reduce nephrotoxicity Transplantation 72 2001 S99 S104
17. Porayko M.K., Textor S.C., and Krom R.A. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation Mayo Clin Proc 69 1994 105 111
18. Wingard J.R. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses Bone Marrow Transplant 19 1997 343 347
19. Walsh T.J., Hiemenz J.W., and Seibel N.L. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases Clin Infect Dis 26 1998 1383 1396
20. Singhal S., Ellis R.W., and Jones S.G. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation Liver Transplant 6 2000 588 595
21. Singh N., Paterson D.L., and Gayowski T. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renalreplacement therapy Transplantation 71 2001 910 913
22. Singh N. Antifungal prophylaxis for solid organ transplant recipients: Seeking clarity amidst controversy Clin Infect Dis 31 2000 545 553
23. Wong-Beringer A., Jacobs R.A., and Guglielmo B.J. Lipid formulations of amphotericin B: Clinical efficacy and toxicities Clin Infect Dis 27 1998 603 618
24. Sharkey P.K., Graybill J.R., and Johnson E.S. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS Clin Infect Dis 22 1996 315 321
25. Ostrosky-Zeichner L., Marr K.A., Rex J.H., and Cohen S.H. Amphotericin B: Time for a new "gold standard" Clin Infect Dis 37 2003 415 425
26. Slain D., Miller K., and Khakoo R. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a universi ty hospital: Aretrospective study Clin Ther 24 2002 1636 1642
27. Linden P., Williams P., and Chan K.M. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections Clin Transplant 14 2000 329 339
28. Perkins W.R., Minchey S.R., and Boni L.T. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity Biochim Biophys Acta 1107 1992 271 282
29. Janoff A.S., Boni L.T., and Popescu M.C. Unusual lipid structures selectively reduce the toxicity of amphotericin B Proc Natl Acad Sci U S A 85 1988 6122 6126
30. Adedoyin A., Bernardo J.F., and Swenson C.E. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase 11 studies Antimicrob Agents Chemother 41 1997 2201 2208
31. Swenson C.E., Perkins W.R., and Roberts P. In vitro and in vivo antifungal activity of amphotericin B lipid complex: Are phospholipases important? Antimicrob Agents Chemother 42 1998 767 771
32. Kan V.L., Bennett J.E., and Amantea M.A. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers J Infect Dis 164 1991 418 421
33. Luke R.G., and Boyle J.A. Renal effects of amphotericin B lipid complex Am J Kidney Dis 31 1998 780 785
34. [published correction appears in Rev Infect Dis. 1991;13:345] Denning D.W., and Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases Rev Infect Dis 12 1990 1147 1201
35. Burch P.A., Karp J.E., and Merz W.G. Favorable outcome of invasive aspergillosis in patients with acute leukemia J Clin Oncol 5 1987 1985 1993
36. Abelcet [package insert]. Bridgewater, NJ: Enzon Pharmaceuticals, Inc.
37. Walsh T.J., Whitcomb P., and Piscitelli S. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis Antimicrob Agents Chemother 41 1997 1944 1948
38. Kline S., Larsen T.A., and Fieber L. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex Clin Infect Dis 21 1995 1154 1158
39. Larkin J.A., and Montero J.A. Efficacy and safety of amphotericin B lipid complex for zygomycosis Infect Med 20 2003 201 206
40. Mehta J., Kelsey S., and Chu P. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologicmalignancies Bone Marrow Transplant 20 1997 39 43
41. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
42. Agresti A. Inference for two-way contingency tables Categorical Data Analysis 1990 John Wiley & Sons New York, NY 47 60
43. SAS The NPARI WAY procedure 4th ed SAS/STAT User's Guide 1989 SAS Institute Inc Cary, NC 1196 1200
44. Ascioglu S., Rex J.H., and de Pauw B. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: Aninternational consensus Clin Infect Dis 34 2002 7 14
45. Kauffman C.A. Fungal infections in older adults Clin Infect Dis 33 2001 550 555
46. Husain S., Alexander B.D., and Munoz P. Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi Clin infect Dis 37 2003 221 229
47. Walsh T.J., Goodman J.L., and Pappas P. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study Antimicrob Agcnis Chemother 45 2001 3487 3496